Literature DB >> 14528049

Huntington's disease.

Marcy E MacDonald1, Silvia Gines, James F Gusella, Vanessa C Wheeler.   

Abstract

Huntington's disease (HD) research is aimed at understanding the root cause of the disorder, for the thrill of uncovering new biology, and for the serious purpose of finding effective therapeutic agents. Molecular genetics has revealed the disease trigger, an inherited unstable CAG expansion in a novel 4p16.3 gene (HD), that lengthens a polyglutamine segment in huntingtin. Now studies with HD patients and model systems that are genetic HD replicas are homing in on the trigger mechanism and the first formative steps that cast HD as a distinct clinical entity. At the same time, assays at the biochemical, cellular, and whole organism levels are starting to yield potential disease modifying genes and candidate drugs. These can be prioritized by testing in a panel of genetic and phenotypic HD mouse models to yield analytical tools for dissecting the early and late stages of the disease process and to maximize the chance of success in trials with HD patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528049     DOI: 10.1385/NMM:4:1-2:7

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   4.103


  80 in total

1.  Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.

Authors:  V Heiser; E Scherzinger; A Boeddrich; E Nordhoff; R Lurz; N Schugardt; H Lehrach; E E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse.

Authors:  V C Wheeler; W Auerbach; J K White; J Srinidhi; A Auerbach; A Ryan; M P Duyao; V Vrbanac; M Weaver; J F Gusella; A L Joyner; M E MacDonald
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

3.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization.

Authors:  A Sawa; G W Wiegand; J Cooper; R L Margolis; A H Sharp; J F Lawler; J T Greenamyre; S H Snyder; C A Ross
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

4.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

5.  Apolipoprotein E and presenilin-1 genotypes in Huntington's disease.

Authors:  M Panas; D Avramopoulos; G Karadima; M B Petersen; D Vassilopoulos
Journal:  J Neurol       Date:  1999-07       Impact factor: 4.849

6.  Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo.

Authors:  E Scherzinger; R Lurz; M Turmaine; L Mangiarini; B Hollenbach; R Hasenbank; G P Bates; S W Davies; H Lehrach; E E Wanker
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

7.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.

Authors:  Y Trottier; Y Lutz; G Stevanin; G Imbert; D Devys; G Cancel; F Saudou; C Weber; G David; L Tora
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

8.  Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways.

Authors:  J Velier; M Kim; C Schwarz; T W Kim; E Sapp; K Chase; N Aronin; M DiFiglia
Journal:  Exp Neurol       Date:  1998-07       Impact factor: 5.330

Review 9.  Alternative excitotoxic hypotheses.

Authors:  R L Albin; J T Greenamyre
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

10.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Authors:  Emma Hockly; Victoria M Richon; Benjamin Woodman; Donna L Smith; Xianbo Zhou; Eddie Rosa; Kirupa Sathasivam; Shabnam Ghazi-Noori; Amarbirpal Mahal; Philip A S Lowden; Joan S Steffan; J Lawrence Marsh; Leslie M Thompson; Cathryn M Lewis; Paul A Marks; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

View more
  29 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Lentiviral vectors for the central nervous system.

Authors:  Elena Armandola
Journal:  MedGenMed       Date:  2004-09-24

3.  Firing up the nature/nurture controversy: bioethics and genetic determinism.

Authors:  I de Melo-Martín
Journal:  J Med Ethics       Date:  2005-09       Impact factor: 2.903

4.  Selective reduction of amyloid beta42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid beta peptide aggregation.

Authors:  B Mollenhauer; M Bibl; H Esselmann; P Steinacker; C Trenkwalder; P Brechlin; J Wiltfang; M Otto
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

5.  Poly-glutamine expanded huntingtin dramatically alters the genome wide binding of HSF1.

Authors:  Laura Riva; Martina Koeva; Ferah Yildirim; Leila Pirhaji; Deepika Dinesh; Tali Mazor; Martin L Duennwald; Ernest Fraenkel
Journal:  J Huntingtons Dis       Date:  2012

6.  Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts.

Authors:  Luana Naia; I Luísa Ferreira; Teresa Cunha-Oliveira; Ana I Duarte; Márcio Ribeiro; Tatiana R Rosenstock; Mário N Laço; Maria J Ribeiro; Catarina R Oliveira; Frédéric Saudou; Sandrine Humbert; A Cristina Rego
Journal:  Mol Neurobiol       Date:  2014-05-20       Impact factor: 5.590

7.  Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains.

Authors:  Guang Bai; Iris Cheung; Hennady P Shulha; Joana E Coelho; Ping Li; Xianjun Dong; Mira Jakovcevski; Yumei Wang; Anastasia Grigorenko; Yan Jiang; Andrew Hoss; Krupal Patel; Ming Zheng; Evgeny Rogaev; Richard H Myers; Zhiping Weng; Schahram Akbarian; Jiang-Fan Chen
Journal:  Hum Mol Genet       Date:  2014-12-05       Impact factor: 6.150

8.  Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.

Authors:  Paola Paoletti; Ingrid Vila; Maria Rifé; José Miguel Lizcano; Jordi Alberch; Silvia Ginés
Journal:  J Neurosci       Date:  2008-10-01       Impact factor: 6.167

9.  Atomistic simulations of the effects of polyglutamine chain length and solvent quality on conformational equilibria and spontaneous homodimerization.

Authors:  Andreas Vitalis; Xiaoling Wang; Rohit V Pappu
Journal:  J Mol Biol       Date:  2008-09-18       Impact factor: 5.469

10.  Vaccinia-related kinase 2 mediates accumulation of polyglutamine aggregates via negative regulation of the chaperonin TRiC.

Authors:  Sangjune Kim; Do-Young Park; Dohyun Lee; Wanil Kim; Young-Hun Jeong; Juhyun Lee; Sung-Kee Chung; Hyunjung Ha; Bo-Hwa Choi; Kyong-Tai Kim
Journal:  Mol Cell Biol       Date:  2013-12-02       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.